The vitamin D therapy market is projected to reach USD 4.7 billion by 2027 from USD 2.2 billion in 2020, at a CAGR of 11.6 % during the forecast period. Vitamin D refers to the group of the fat- soluble steroids which helps in the absorption the calcium, minerals and phosphates. Vitamin D is directly produced in the body by the exposure of sunlight, other sources include cod liver oil, sea food, dairy products, cereals, egg and mushrooms etc.
The main use of vitamin D in the body is to bone formation, mineralization, growth, and reduce inflammation. Vitamin D is also useful in the strengthening of the immune system and muscle strength. Vitamin D deficiency means low amount of serum Vitamin D i.e., <75 nmol/L. Vitamin D deficiency leads bone mineralization impairment and leading to the softening of the bones which finally leads to rickets in the children, osteocalcin and osteoporosis in the adults. Main symptoms include increased risk of fractures, depression, back pain, weakness, muscles pains and advancement of cancer etc. The treatment includes mainly vitamin D supplements, dietary food and exposure to sunlight. Vitamin D can be used in any age group because of less side effects. The main side effect associated with vitamin D is overdose and vitamin D can be used for long term under regular supervision of vitamin D levels in the body. Imbalanced diet in the underdeveloped countries and high incidence rate of Vitamin D deficiency in the rest of the globe is main driving force for the vitamin D deficiency treatment market. Vitamin D deficiency is observed in all age groups, due to this there is high need for Vitamin D supplements in the market the manifestations due to vitamin D deficiency is ranging from bone disorder to cancer and this makes healthcare facilities and government agencies to put more focus towards vitamin D deficiencies. Natural availability of Vitamin D is less and this leads to the inclination towards vitamin D supplements. Other implications like obesity and sedentary life style are also driving vitamin D deficiency treatment market to control the disorders. Geographical area is also one of the reasons for the vitamin D deficiency where sun light exposure is less. Increased geriatric population and consumer awareness regarding vitamin D deficiency implications leading towards more growth in vitamin D deficiency treatment market.
Less availability of vitamin D therapies in the underdeveloped countries leads low growth rate in the vitamin D deficiency treatment market. Government policies also act as a constraint in the growth of vitamin D deficiency market due to the toxicity of the high doses of the vitamin D.
Some of the prominent players in the market are Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd (India).
The vitamin D therapy market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). The Asia Pacific dominated the market in 2018 and is expected to register the highest CAGR during the forecast period. Growth in the APAC is largely driven by the increasing awareness about vitamin D deficiency and supportive government policies and programs for the implementation of vitamin D deficiency treatment plans, heavy air pollution, sedentary lifestyles, increasing incidence of vitamin D deficiency, atypical diets, decreasing sun exposure, and rising malnutrition levels.
Report : Vitamin D Therapy Market - By Route Of Administration (Oral and Parenteral), By Purchasing Pattern (Prescription Drugs, Over-The-Counter Drugs), By Application (Osteoporosis, Rickets, Muscle Weakness, Autoimmune Disorders, Skin Diseases, And Other) And By Age Group (Children, Adults, Senior Adults) and By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027